Delivery Order SPE2DB24D1104-SPE2DB25FXTY6

Award Date 10/30/24
Potential Completion Date 10/31/24
Potential Value $2.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award from the Defense Logistics Agency (DLA) was issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,333.48 firm-fixed-price delivery order is for the supply of Lacosamide 10 mg/ml solution, a pharmaceutical product. The contract has an ultimate completion date of January 28, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award, valued at $1,254.96, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office division. The award is for the delivery of Lacosamide 10 mg/ml Solution 200 ml, a pharmaceutical product. The contract has a firm fixed price pricing type and a completion date of September 23, 2024. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 between Amerisourcebergen and the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,118.64, is for the delivery of Lacosamide 10 mg/ml solution in 200 ml containers. The contract is a Delivery Order with a Firm Fixed Price pricing type, and the ultimate completion date is March 3, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) held by...
This federal contract award, valued at $1,352.73, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of LACOSAMIDE 150 MG TABLET 60S, with an ultimate completion date of March 17, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026....
This award is for a Delivery Order contract with Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, to provide Lacosamide 50 mg/5 ml cup UD 5 ml to the U.S. Department of Defense's Medical Supply Chain. The award has a ceiling value of $3,000.36 and an ultimate completion date of June 11, 2024. The contract is a Firm Fixed Price arrangement, without any set-aside designations. Amerisourcebergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the Defense...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,415.48, is a delivery order under the company's existing Indefinite Delivery Contract (IDC) with the DLA, worth $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical...
This federal contract award, valued at $11,193.44, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under the company's existing Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for Amerisourcebergen to supply a comprehensive range of...
This federal contract award, valued at $111,908.16, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under the company's existing Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, worth up to $999,999,999 through November 2026. This IDC serves as a primary vehicle for AmerisourceBergen to provide a comprehensive range of pharmaceutical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,101.60, is a delivery order for pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and other critical medical commodities. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the...
This federal contract award, valued at $24,738.74, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under the company's existing Indefinite Delivery Contract (IDC) with the DLA, which is valued at $999,999,999 and runs through November 2026. This IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of...
  • SPE2DB24D1104
    Indefinite Delivery Contract
  • SPE2DB24D1104-SPE2DB25FXTY6
    Delivery Order

This federal contract award, with ID SPE2DB24D1104|SPE2DB25FXTY6, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, which is not designated as a set-aside, is a Delivery Order valued at $2,143.78 for the supply of Lacosamide 10 mg/ml solution in 200ml quantities.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 5/20/25, 2:23 PM